You are here: Industry Insights > Proxalutamide

News List

With First Chinese Small-molecule Oral Drug for COVID-19 Coming, What New Opportunities are Ushered in by the Relevant Industry Chain？ PharmaSources.com/Yefenghong
May 23, 2022
News about the progress of Chinese small-molecule oral antiviral drug for COVID-19 has been disclosed in recent days and the related R&D ushers in a critical point.
Kintor Pharma Announces First Patient Dosing in China in Phase III Clinical Trial of Proxalutamide for the Treatment of COVID-19 Outpatients prnasia
February 14, 2022
Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics...
Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19 prnasia
December 28, 2021
Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today provided an update on its multi-regional study...
Kintor Pharma Announces Brazil's ANVISA Approves Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients prnasia
September 28, 2021
Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics...
Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay prnasia
July 16, 2021
Kintor today announced that Paraguay's Ministry of Public Health and Social Welfare (MSPBS) has granted an emergency use authorization (EUA) for proxalutamide to treat hospitalized patients with COVID-19 infections at the MSPBS hospitals.
Kintor partners with Fosun to market Covid-19 therapy in India and Africa pharmaceutical-technology
July 15, 2021
Kintor Pharmaceutical has signed a licensing agreement with Shanghai Fosun Pharmaceutical Development to market its drug, proxalutamide, for Covid-19 in India and 28 African countries.
Kintor Announced (1) FDA Has Greenlighted Proxalutamide's Phase III Study for Hospitalized Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide's prnasia
May 20, 2021
On May 18, Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the U.S. Food and Drug Administration (FDA) has greenlighted proxalutamide's phase III ...
Kintor, Visum Enter COVID-19 Manufacturing Partnership contractpharma
April 20, 2021
Kintor Pharmaceutical, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, has entered a partnership with Hainan Visum Pharmaceutical to expand proxalutamide manufacturing.
Kintor Pharmaceutical and Visum Announced Strategic Partnership to Expand Proxalutamide Manufacturing prnasia
April 15, 2021
Kintor Pharmaceutical Limited recently announced a strategic partnership with Hainan Visum Pharmaceutical Limited to expand proxalutamide manufacturing.
Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients prnasia
March 11, 2021
Kintor Pharmaceutical Limited announced top-line results from its investigator-initiated Brazil trial evaluating the efficacy of Proxalutamide relative to standard of care as assessed by the COVID-19 ordinal scale.

Previous page 1 2 Next page